118 related articles for article (PubMed ID: 38477854)
1. Fatigue, depression, and sleep disorders are more prevalent in patients with metabolic-associated fatty liver diseases.
Mostafa AM; Hafez SM; Abdullah NM; Fouad Y
Eur J Gastroenterol Hepatol; 2024 May; 36(5):665-673. PubMed ID: 38477854
[TBL] [Abstract][Full Text] [Related]
2. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
3. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population.
Deng D; George J; Pasupathy D; Wah Cheung N
Diabetes Res Clin Pract; 2021 Apr; 174():108757. PubMed ID: 33744378
[TBL] [Abstract][Full Text] [Related]
6. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
7. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study.
Attia D; Abdel Alem S; El-Akel W; Abdel-Razek W; Eslam M; Fouad Y; Waked I
Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1581-1590. PubMed ID: 36168675
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease.
Liu J; Lv H; Wang J; Zhu Q; Chen G; Jiang Y; Zhao K; Shao L; Shi J; Pan X
Ann Hepatol; 2023; 28(2):100892. PubMed ID: 36577468
[TBL] [Abstract][Full Text] [Related]
12. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
14. J-Shaped Relationship Between Serum Prolactin and Metabolic-Associated Fatty Liver Disease in Female Patients With Type 2 Diabetes.
Zhu C; Ma H; Huang D; Li G; Gao J; Cai M; You H; Bu L; Qu S
Front Endocrinol (Lausanne); 2022; 13():815995. PubMed ID: 35222274
[TBL] [Abstract][Full Text] [Related]
15. Sleep factors were associated with a higher risk of MAFLD and significant fibrosis.
Li Y; Tan S
Sleep Breath; 2024 Jun; 28(3):1381-1391. PubMed ID: 38514588
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
18. Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease.
Sato S; Kawai H; Sato S; Iwasaki H; Omori M; Kita Y; Ikeda Y; Awatsu T; Murata A; Taniguchi G; Shimada Y; Genda T
BMC Gastroenterol; 2022 Nov; 22(1):478. PubMed ID: 36411436
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
[TBL] [Abstract][Full Text] [Related]
20. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]